Market research
VKTX Viking Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 92.3947
- Dividend yield
- Not available
- Beta
- 0.69
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US92686J1060
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 92.3947
- Dividend yield
- Not available
- Beta
- 0.69
About
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the VKTX discussion.
5 years, 4 months ago
Viking Therapeutics, Inc is currently in a long term downtrend where the price is trading 2.5% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Viking Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 100.0% to $0 since the same quarter in the previous year.
Finally, its free cash flow grew by 53.3% to $-5M since the same quarter in the previous year.
Based on the above factors, Viking Therapeutics, Inc gets an overall score of 3/5.